肝硬化合并新型冠状病毒感染的临床特征和管理

关键词：肝硬化；新型冠状病毒肺炎；COVID-19疫苗；临床管理基金项目：南昌大学第二附属医院博士启动基金（B2273）；北京肝胆相照公益基金会临床科研专项资助基金（iGandanF-1082024-LG009）；北京肝胆相照公益基金会人工肝专项基金（RGGJJ-2021-028）

Clinical featuresand managementof liver cirhosis comorbid with severe acute respiratory syndromecoronavirus 2 infection

JIANGWenli，YANGWenlong，LUOLei

DepartmentofInfectiousDiseases，TheSecondAfliatedHospitalofNanchang Unversity，Nanchang33oo6，China

Correspondingauthors：YANG Wenlong，wenlooyang@163.com（ORCID：00-03-3756-7468）；LUOLei，zgl1990@163.com （ORCID： 0000-0002-7999-9560）

Abstract：Patientswith livercirhosisare moresusceptible tovarious bacterialorviralinfectionsdue toimmunedysfunction. Recentstudieshaveshownthatcompared with thegeneralpopulation，individuals with livercirrhosisshowasignificantincreasein theicidencerateofadverseoutcomesaftersevereacuterespiratorysyndromecoronavirus2infection，includingtheprogressionof liverinjuryandtheincreaseinmortalityrate.Vaccinationcanreducetheincidenceratesofbreakthroughinfectionsandsevere coronavirus disease 2019（COVID-19）inpatientswith liver cirhosis，butsuchpatients have lowimmuneresponse and hus requireboosterdoses toenhance immunity.Thisarticlereviews theclinicalfeaturesofirroticpatients withCOVID-19andrelated management strategies，inorder toprovideevidence-basedgudancefortheclinicaldiagnosisandtreatmentofsuchpatients.

Key Words： Liver Cirrhosis;COVID-19；COVID-19 Vaccines；Clinical Governance

Researchfunding：DoctoralStart-upFundoftheSecondAfiliatedHospitalofNanchangUniversity（B273）；ClincalResearch SpecialFundof BeijingiGandan Foundation（iGandanF-1082024-LGo9）；ArtificialLiver SpecialFundofBeijingiGandan Foundation（RGGJJ-2021-028）

新型冠状病毒感染（coronavirusdisease 2019，COVID-19）是由新型冠状病毒（severe acuterespiratorysyndromecoronavirus-2，SARS-CoV-2）引起的一种传染性疾病。（剩余16991字）